Ibrutinib Common in CLL Patients Excluded from Clinical Trials

Ibrutinib demonstrated superior response rates and survival in certain CLL patients despite exclusion from major clinical trials.

Source: CancerNetwork - September 5, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news